Hims & Hers Health, Inc. (HIMS) call put ratio 1.4 calls to 1 put into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- Harry and Meghan surprised by King Charles' letter on their status
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- S&P 500 falls as AI worries hit software makers
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Hims and Hers (HIMS) PT Lowered to $48 at Jefferies, 'want to see proof points of consumer traction'
November 4, 2025 8:06 AM ESTJefferies analyst Glen Santangelo lowered the price target on Hims and Hers (NYSE: HIMS) to $48.00 (from $51.00) while maintaining a Hold rating.
The analyst comments "HIMS delivered a solid Q3, with revs, EBITDA, & EPS beating Street ests by 3%, 15%, & 30% respectively. EBITDA margins of 13.1% beat Street... More
Needham on Hims and Hers (HIMS): 'we believe this incremental near-term investment and likely growing pains'
November 4, 2025 5:13 AM ESTNeedham analyst Ryan MacDonald reiterated a Hold rating on Hims and Hers (NYSE: HIMS).
The analyst comments "We are reiterating our Hold rating on Hims & Hers Health (HIMS) following the company's earnings print in which a 3Q beat was offset... More
BTIG Hims and Hers (HIMS): 'MAHA is being Implemented through HIMS with Proactive Health'
November 4, 2025 4:35 AM ESTBTIG analyst David Larsen reiterated a Buy rating and $85.00 price target on Hims and Hers (NYSE: HIMS).
The analyst comments "On Monday, 11/3/25 AMC, HIMS reported good 3Q:25 results. Revenue of $599M +49% y/y exceeded BTIG / consensus / guidance of $580.1M / $580M / $570M-$590M and adjusted EBITDA of $78.4M +53% y/y also came in well ahead of BTIG / consensus / guidance of $70.5M / $68M / $60M-$70M. HIMS... More
